Cannabis Use Didn't Derail Intensive PTSD Treatment for Veterans

Veterans who used cannabis before or during intensive PTSD treatment programs showed similar symptom improvement to non-users — cannabis use didn't appear to undermine treatment effectiveness.

Schubert, Ryan A et al.·Psychological trauma : theory·2026·Preliminary EvidenceObservational·1 min read
RTHC-08609ObservationalPreliminary Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Preliminary Evidence
Sample
N=741
Participants
N=741 veterans, mixed gender, undergoing intensive PTSD treatment in the US.

What This Study Found

Across two samples of veterans undergoing Cognitive Processing Therapy-based intensive treatment programs (3-week program: N=488; 2-week program: N=253), researchers examined whether cannabis use frequency before or during treatment affected PTSD and depression outcomes.

Veterans in both programs reported low rates of cannabis use overall. The central finding was that cannabis use frequency — whether measured before treatment or concurrently — was not significantly associated with different trajectories of PTSD or depression symptom improvement over time.

Both cannabis-using and non-using veterans showed significant reductions in PTSD (measured by PCL-5) and depressive symptoms (measured by PHQ-9) from pre- to post-treatment. The treatment appeared to work regardless of cannabis use status.

This finding held across both the 3-week and 2-week program formats, providing replication across two independent samples with slightly different treatment intensities.

Key Numbers

Two samples: N=488 (3-week ITP) and N=253 (2-week ITP). Cannabis use frequency not significantly associated with PTSD or depression symptom change trajectories. Both users and non-users showed significant symptom improvement on PCL-5 and PHQ-9.

How They Did This

Observational study of two veteran samples in Cognitive Processing Therapy-based intensive treatment programs (N=488 for 3-week; N=253 for 2-week). Cannabis use frequency self-reported over past 2 weeks. PTSD measured by PCL-5, depression by PHQ-9, assessed before, during, and after treatment. Linear mixed-effects models analyzed cannabis use frequency effects on symptom trajectories.

Why This Research Matters

Some treatment programs exclude or discourage cannabis-using patients, and clinicians may worry that cannabis use undermines evidence-based PTSD therapy. This study provides reassurance that cannabis use at the levels observed didn't appear to interfere with intensive treatment — meaning cannabis-using veterans shouldn't necessarily be excluded from these programs.

The Bigger Picture

This study presents an interesting contrast with the abstinence study (RTHC-00274), which found that quitting cannabis produced larger PTSD improvements. The key difference: this study asked whether cannabis use undermines treatment (answer: no), while the abstinence study asked whether quitting cannabis enhances improvement (answer: possibly yes). Both can be true — cannabis may not prevent therapy from working, but quitting might allow it to work even better. The veteran harm reduction study (RTHC-00267) adds the patient perspective on why veterans continue using during treatment.

What This Study Doesn't Tell Us

Low overall rates of cannabis use in these samples may have limited statistical power to detect effects. Self-reported cannabis use likely underestimates actual use in a treatment setting. Observational design — cannabis-using and non-using veterans may differ in unmeasured ways. Intensive treatment programs are a specific context; results may not generalize to standard outpatient PTSD therapy.

Questions This Raises

  • ?Would heavier cannabis use (not captured in these low-use samples) interfere with treatment more than light use?
  • ?Could cannabis use actually enhance treatment engagement for some veterans by reducing avoidance?
  • ?Is there a level of cannabis use above which treatment outcomes start to diverge?

Trust & Context

Key Stat:
Evidence Grade:
Observational study with two independent replication samples — strengthened by consistency across both programs but limited by low cannabis use rates and observational design.
Study Age:
Published in 2026, addressing a practical clinical question relevant to the growing overlap between cannabis use and PTSD treatment seeking.
Original Title:
Impact of self-reported cannabis use on veterans' intensive PTSD treatment outcomes.
Published In:
Psychological trauma : theory, research, practice and policy, 18(3), 628-637 (2026)Psychological Trauma is a reputable journal focusing on trauma research and its implications for practice.
Database ID:
RTHC-08609

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Read More on RethinkTHC

Cite This Study

RTHC-08609·https://rethinkthc.com/research/RTHC-08609

APA

Schubert, Ryan A; Splaine, Cailan C; Montes, Mauricio M; Pridgen, Sarah A; Kaysen, Debra L; Held, Philip. (2026). Impact of self-reported cannabis use on veterans' intensive PTSD treatment outcomes.. Psychological trauma : theory, research, practice and policy, 18(3), 628-637. https://doi.org/10.1037/tra0001842

MLA

Schubert, Ryan A, et al. "Impact of self-reported cannabis use on veterans' intensive PTSD treatment outcomes.." Psychological trauma : theory, 2026. https://doi.org/10.1037/tra0001842

RethinkTHC

RethinkTHC Research Database. "Impact of self-reported cannabis use on veterans' intensive ..." RTHC-08609. Retrieved from https://rethinkthc.com/research/schubert-2026-impact-of-selfreported-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.